BIOMERIEUX SA

Their core work

bioMérieux is a major French in-vitro diagnostics company specializing in infectious disease detection, antimicrobial resistance testing, and biomarker-based diagnostic platforms. In H2020 projects, they contribute diagnostic assay development, biosensor technology, and microfluidics expertise to large multi-partner consortia tackling sepsis, febrile illness, and antimicrobial resistance. Their work bridges clinical laboratory diagnostics with translational research, providing the industrial capacity to validate and scale molecular diagnostic tools developed in academic settings.

What they specialise in

How they've shifted over time

In 2015–2018, bioMérieux focused on foundational infectious disease research — understanding bacterial spore biology (CLOSPORE), developing sepsis biomarkers (ESA-ITN), and building febrile illness diagnostics (PERFORM) with emphasis on distinguishing bacterial from viral infections. From 2019 onward, their portfolio shifted decisively toward precision medicine and personalized approaches: RNA-based molecular diagnosis (DIAMONDS), personalized immunotherapy for sepsis (ImmunoSep), and viral load monitoring for transplant patients (TTV GUIDE TX). There is also a notable expansion into public health dimensions — vaccination economics, AMR health economics, and disease burden modelling through VITAL and VALUE-Dx.

bioMérieux is moving from broad infectious disease detection toward personalized molecular diagnostics and immune response monitoring — making them an increasingly relevant partner for precision medicine consortia.

How they like to work

bioMérieux operates exclusively as a participant — they have never coordinated an H2020 project, preferring to contribute industrial diagnostic expertise to large, multi-partner consortia (161 unique partners across 27 countries). Their consistent role as a non-coordinating industry partner suggests they function as a key technology provider and validation site, bringing commercial diagnostic platforms and clinical data access without taking on administrative project leadership. This makes them a reliable, low-friction partner for academic-led consortia that need industrial diagnostic capacity.

bioMérieux has built one of the broadest partner networks among diagnostics companies in H2020, collaborating with 161 unique partners across 27 countries. Their network spans academic medical centers, public health institutes, and biotech SMEs across virtually all EU member states, reflecting the pan-European reach of the large IMI and RIA consortia they join.

What sets them apart

bioMérieux brings something rare to EU consortia: the full chain from biomarker discovery to commercial diagnostic test, backed by a global IVD company with regulatory and manufacturing capacity. Unlike academic partners who stop at proof-of-concept, bioMérieux can validate, scale, and bring diagnostic innovations to market. Their participation in both IMI2 (industry-driven) and standard RIA/MSCA projects shows they bridge the gap between pharma-scale clinical trials and fundamental research training networks.

Highlights from their portfolio

• TTV GUIDE TX
  Largest single EC contribution (EUR 801,750) and a Phase II clinical trial — rare for H2020 — testing viral load as a biomarker for personalizing immunosuppression after kidney transplantation.
• DIAMONDS
  Represents the frontier of their diagnostic work: RNA-based personalized molecular signatures for managing febrile illness, building directly on earlier PERFORM project results.
• VALUE-Dx
  Tackles the economic case for diagnostics in AMR — a strategic pivot from pure technology development to health economics and policy influence around diagnostic value.